Recaf detects 90% of cancers, is a universal cancer marker and is highly specific and sensitive. Over 5,000 patients have already be tested using Biocurex's Recaf test.

Currently there is no cancer marker for breast or lung cancer however, Recaf detects lung cancer with a 95% accuracy and breast cancer with a 95% accuracy

Recaf also detects stage I and stage II breast cancer and prostrate cancer where if these cancers are detected early enough cures can be initiated

The PSA test is only 40 % accurate and can not distinguish between malignancies and an enlarged prostate. The current market for the PSA test is $500 million/year. Recaf can distinguish between malignancies and an enlarged prostrate and when combined with Recaf the PSA test accuracy increases to 100%. Abbott sells 15 million PSA test per year. Per Biocurex's agreement with Abbott, they are required to pay Biocurex a minimum royalty of $2/test, so when used in conjunction with the PSA test that would yield Biocurex $30 million per year from their licnese agreement with Abbott.

CEA which was developed by Dr. Phil Gold, one of Biocurex's board of directors, is only 50% accurate yet has a $300 million/year market. When combined with Recaf the accuracy increases to 90%

Inverness has 5,000 automated analyzers in the field and are also required to pay Biocurex a minimum royalty of $2/test when using Recaf.

Revenue for 2010

Biocurex anticipates revenue from their veterinary application the 1st quater of 2010. They planto generate revenue from 2 stages. The first stage will require Biocurex to send a kit to the vet, he puts a sample of blood on the swab and sends the kit back to the lab for analysis. The 2nd stage which is anticipated by the second half of the year would allow the vets to receive the POC rapid test which can be used by them in their facility which will yield faster results. It should also be noted that 40% of the canine deaths result from cancer. The current test to rule out cancer is an expensive ultrasound which can be replaced by the inexpensive Recaf test.

Biocurex anticipates revenue from their non-automated test in the 2nd quarter of 2010 from their China project in Shaghai, which will be marketed in China, India and Mexico. Initially they will target cities in China with a population of 10 - 20 million people.

Biocurex anticipates signing a third license for the automated application the end of third quarter of 2010. Biocurex will also receive their 1st royalty payment from Inverness this year.

The key aspect going forward is the rapid POC test. Thay have already completed the feasibity studies and have contracted two companies to conduct test, one for the patient application and one for the veterinary application. Trinity Biotech in Ireland for the patient test and Quantrix in Portland for the canine application.

Also in 2010 they will finish the contracted development work on the rapid POC test. They will also submit the CLIA waiver for insurance reimburesment.

They will sign a development agreement to manufacture a cassette for Abbott's architect system which confirms Abbott is still interested in the technology.

Trinity Biotech will develop the POC rapid test and submit it to the FDA for approval as a type II medical device which only takes 90 days for approval once submitted. It should be noted that Trinity Biotech in it's 15 year history has submitted 34 POC test to the FDA process for approval, which confirms their proven track record. Dr. Burger is also a founding chairman of Trinity Biotech.

The POC rapid test will be use as follow-up application for cancer patients that have had surgery. Currently over 10 million people have een diagnosed with cancer. Current follow-up test usually cost between $2,000 - $5000 per patient. This cost can greatly be reduced by a Recaf test.

Hope this information is helpful. It was taken from the presentation by Dr. Burger, Dec. 05, 2009. It was very hard to hear the presentation because the volume was so low. Please make sure you do your own due dilligence when making investment decisions.